Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor ii potentiates antitumor immunity

Oncotarget

Volumn 5, Issue 20, 2014, Pages 10100-10113

  Van der Jeught, Kevin ^a   Joe, Patrick Tjok ^a   Bialkowski, Lukasz ^a   Heirman, Carlo ^a   Daszkiewicz, Lidia ^a   Liechtenstein, Therese ^b   Escors, David ^b,c   Thielemans, Kris ^a   Breckpot, Karine ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Atención Primaria Y Promoción de La Salud   (Spain)

Author keywords

Cancer therapy; IFN ; mRNA; T cell; TGF

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; FUSOKINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; HYBRID PROTEIN; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; IN VITRO STUDY; LYMPHOMA; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; C57BL MOUSE; GENE THERAPY; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INTRALESIONAL DRUG ADMINISTRATION; LUNG NEOPLASMS; LYMPHOMA, T-CELL; MELANOMA, EXPERIMENTAL; NEOPLASMS; PROCEDURES; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; GENETIC THERAPY; HEK293 CELLS; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; INTERFERON-BETA; LUNG NEOPLASMS; LYMPHOMA, T-CELL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TUMOR MICROENVIRONMENT;

EID: 84919889199     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Frey AB. Signaling defects in anti-tumor T cells. 2008: 192-205.
2. Emeagi PU, Goyvaerts C, Maenhout S, Pen J, Thielemans K, Breckpot K. Lentiviral vectors: a versatile tool to fight cancer. Curr. Mol. Med. 2013; 13:602-25.
3. Marabelle a, Kohrt H, Caux C, Levy R. Intratumoral Immunization: A New Paradigm for Cancer Therapy. Clin. Cancer Res. 2014; 20:1747-1756.
4. Van Lint S, Renmans D, Benteyn D, Goyvaerts C, Maenhout S, Broos K, Du four S, Goethals L, Van der Jeught K, Bialkowski L, Heirman C, Thielemans K, Breckpot K. Intratumoral immunotherapy using mRNA encoding CD40 Ligand, active TLR4 and CD70. JNCI 2014. Under revision.
5. Van Lint S, Renmans D, Broos K, Dewitte H, Lentacker I, Heirman C, Breckpot K, Thielemans K. The ReNAissanCe of mRNA-based cancer therapy. Exp. Rev. Vaccines. Accepted 2014.
6. Van Lint S, Maenhout S, Benteyn D, Heirman C, Breckpot K, Thielemans K. Intratumoral and Intranodal Administration of Trimix and Antigen MRNA Results in Effective Anti-tumor Immunity. J. Immunother. 2012; 35: 745-745.
7. Penafuerte C, Bautista-Lopez N, Bouchentouf M, Birman E, Forner K, Galipeau J. Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptordriven STAT1 activation. J. Immunol. 2011; 186: 6933-6944.
8. Penafuerte C, Galipeau J. FIST, a sword and shield fusokine for cancer immunotherapy. Oncoimmunology. 2012; 1:224-226.
9. Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonning S, McPherson JM, Berzofsky JA. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin. Cancer Res. 2009; 15:6560-9.
10. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011; 208:1989-2003.
11. Arce F, Breckpot K, Stephenson H, et al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum. 2011; 63:84-95.
12. Liechtenstein T, Perez-Janices N, Blanco-Luquin I, Goyvaerts C, Schwarze J, Dufait I, Lanna A, De Ridder M, Guerrero-Setas D, Breckpot K, Escors D. Antimelanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology. 2014; 3:e29178.
13. Liechtenstein T, Perez-Janices N, Gato M, Caliendo F, Kochan G, Blanco-Luquin I, Van der Jeught K, Arce F, Guerrero-Setas, Fernandez-Irigoyen J, Santamaria E, Breckpot K, Escors D. A highly efficient tumorinfiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget; Adv. Online Publ. 2014.
14. Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annu. Rev. Med. 2013; 64:71-90.
15. Benteyn D, Van Nuffel AMT, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res. Int. 2013; 2013:976383.
16. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, et al. Safety, Activity, and Immune Correlates of Anti- PD-1 Antibody in Cancer. N. Engl. J. Med. 2012; 366: 2443-2454.
17. Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N. Engl. J. Med. 2012; 366:2455-2465.
18. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den EertWegh AJM, Lutzky J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363:711-723.
19. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X, Corbley M, Kaiser LR, Ling L, Albelda SM. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res. 2008; 68:10247-10256.
20. Breckpot K, Corthals J, Bonehill A, Michiels A, Tuyaerts S, Aerts C, Heirman C, Thielemans K. Dendritic cells differentiated in the presence of IFN-beta and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. J. Leukoc. Biol. 2005; 78:898-908.
21. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 2000; 191:1777-88.
22. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 2011; 208: 2005-16.
23. Narumi K, Udagawa T, Kondoh A, Kobayashi A, Hara H, Ikarashi Y, Ohnami S, Takeshita F, Ochiya T, Okada T, Yamagishi M, Yoshida T, Aoki K. In vivo delivery of interferon-α gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts. Gene Ther. 2012; 19:34-48.
24. Maenhout SK, Van Lint S, Emeagi PU, Thielemans K, Aerts JL. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. Int. J. Cancer. 2014; 134:1077-90.
25. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66:1123-31.
26. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs L, Adany R, Shibata T, Takami T. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-and M2-type characteristics. J. Leukoc. Biol. 2008; 83:1136-44.
27. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009; 182:4499-506.
28. Zoglmeier C, Bauer H, Nörenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 2011; 17:1765-75.
29. Ellermeier J, Wei J, Duewell P, Hoves S, Stieg MR, Adunka T, Noerenberg D, Anders HJ, Mayr D, Poeck H, Hartmann G, Endres S, Schnurr M. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res. 2013; 73:1709-20.
30. Hofbauer GF, Geertsen R, Laine E, Burg G, Dummer R. Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures. Melanoma Res. 2001; 11:213-8.
31. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. 2004; 22:1136-51.
32. Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, Thielemans K, Breckpot K. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014; 21:262-271.
33. Liechtenstein T, Dufait I, Bricogne C, Lanna A, Pen J, Breckpot K, Escors D. PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal. J. Clin. Cell. Immunol. 2013:1-14.
34. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon V, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002; 8:793-800.
35. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer. 2011; 128:887-96.
36. Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M, Escors D. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol. Med. 2011; 3:581-92.
37. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX. Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses. Cancer Cell. 2014; 25:37-48.
38. Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, Limmer A, Jönsson G, Hölzel M, et al. Immune-cell poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014. doi:10.1158/2159-8290. CD-13-0458.
39. Van den Boorn JG, Hartmann G. Turning tumors into vaccines: co-opting the innate immune system. Immunity. 2013; 39:27-37.
40. Arce F, Breckpot K, Stephenson H, Karwacz K, Ehrenstein MR, Collins M, Escors D. Selective ERK Activation Differentiates Mouse and Human Tolerogenic Dendritic Cells, Expands Antigen-Specific Regulatory T Cells, and Suppresses Experimental Inflammatory Arthritis. Arthritis Rheum. 2011; 63:84-95.
41. Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, Pen J, Bonehill A, Heirman C, Breckpot K, Thielemans K. Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy. Cancer Res. 2012; 72:1661-1671.
42. Van Meirvenne S, Straetman L, Heirman C, Dullaers M, De Greef C, Van Tendeloo V, Thielemans K. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther. 2002; 9:787-97.
43. Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J. Gene Med. 2003; 5:654-667.